FHA
LGND icon

Flagship Harbor Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Flagship Harbor Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$189 – 1554
2025
Q4 		$189 Buy
+1
New +$192 ﹤0.01% 2182

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Nomura Asset Management International
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Flagship Harbor Advisors's LGND Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 1 share — an estimated $189 sold.

Flagship Harbor Advisors first reported a position in LGND in Q4 2025 and held it in 1 quarter. The position peaked at $189 in Q4 2025. 359 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 1 Ligand Pharmaceuticals share in Q1 2026, an estimated $189.
  • Flagship Harbor Advisors first reported a position in Ligand Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Flagship Harbor Advisors's Ligand Pharmaceuticals position peaked at $189 in Q4 2025.
  • 359 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.